Assessing Temporal Changes in Retinal Non-Perfusion Using Ultra-Widefield Fluorescein Angiography After Intravitreal Therapy for Diabetic Retinopathy - Scorecard - MDSpire
Advertisement
Assessing Temporal Changes in Retinal Non-Perfusion Using Ultra-Widefield Fluorescein Angiography After Intravitreal Therapy for Diabetic Retinopathy
Clinical Scorecard: Assessing Temporal Changes in Retinal Non-Perfusion Using Ultra-Widefield Fluorescein Angiography After Intravitreal Therapy for Diabetic Retinopathy
At a Glance
Category
Detail
Condition
Key Mechanisms
Target Population
Patients aged 18 years or older with type 1 or 2 diabetes mellitus, including those with varying stages of diabetic retinopathy.
Care Setting
Key Highlights
Ultra-widefield fluorescein angiography captures 82% of the retinal surface area, improving detection of peripheral lesions.
Guideline-Based Recommendations
Diagnosis
Management
First-line treatment for center-involving diabetic macular edema includes intravitreal anti-VEGF agents.
Consider individualized treatment plans based on the stage of diabetic retinopathy.
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Fixed dosing of anti-VEGF may be necessary to sustain improvements in DR severity; monitor for side effects such as intraocular pressure changes.
Clinical Best Practices
Employ UWF FA for comprehensive assessment of peripheral retinal areas.
Consider combination therapy with anti-VEGF and pan-retinal photocoagulation for PDR.
Educate patients on treatment options and expected outcomes.
